3 ms·
This will be great for pharmaceutical profits, not so great for insurance premiums.
by jrochkind1 8y ago
This will be great for pharmaceutical profits, not so great for insurance premiums.
- tonyedgecombe 8y agoProbably not very good for patients either.
- openasocket 8y agoI think if anything this would slightly lower insurance premiums, since insurance generally doesn't cover nonprescription medications. As for the effect on pharmaceutical companies, it could go either way. On one hand, it makes it much easier for customers to buy them. On the other, the customer is paying for it out of pocket, and the price is right there on the box. If there are multiple drugs that treat the same condition, customers will take into account price when choosing which one to buy, and so you'll start to see the effects of a free market encouraging competition and driving down prices. Of course, if there isn't any competition for that drug category they can make the price whatever they want and the poor will wind up screwed.
- ars 8y agoYou have that 100% backwards. Insurance premiums will go down since OTC drugs are not covered by insurance. Pharmaceutical profits will also go down because people are much more price sensitive for OTC drugs, so they can't charge as much.
- darpa_escapee 8y agoI could be wrong, but I was under the impression that some plans will cover OTC medication if a doctor "prescribes" them for you. According to the article, these drugs won't be considered OTC, they still need a pharmacists approval. I don't know how that will affect coverage, if at all.
- ars 8y ago> I could be wrong, but I was under the impression that some plans will cover OTC medication if a doctor "prescribes" them for you. Yes, that is correct. But the idea here is to have a person decide to take it without having a Dr prescribe it, so insurance will not cover it.
- rz2k 8y agoWhy wouldn't it have the opposite effect? Patients aren't price sensitive when their insurance provider is paying. It creates a suboptimal three (or four) party pricing problem. It seems like it would be preferable if patients chose whether to follow a physician's instructions based on whether they got sufficient utility or quality of life improvements from the pharmaceutical to justify the cost. Likewise, if patients incur lower costs on the insurance provider their business is more valuable, and competing insurance providers will try to undercut them resulting in lower prices. The only "loser" in this scenario seems to be the pharmaceutical companies, which will come in the form of a combination of short term reduced shareholder profits, and long term slower pharmaceutical research. However, it is not difficult to argue that if drug expenditures are too high, it ultimately comes down to paying the bills for over investment in research rather than the cost of production.